€ million |
|
Q1 2025 |
|
Q1 2026 |
|||
|---|---|---|---|---|---|---|---|
Net sales |
|
13,738 |
|
13,405 |
|||
Cost of goods sold |
|
(5,625) |
|
(5,232) |
|||
Gross profit |
|
8,113 |
|
8,173 |
|||
Selling expenses |
|
(3,159) |
|
(3,164) |
|||
Research and development expenses |
|
(1,458) |
|
(1,419) |
|||
General administration expenses |
|
(548) |
|
(532) |
|||
Other operating income |
|
205 |
|
810 |
|||
Other operating expenses |
|
(829) |
|
(340) |
|||
EBIT1 |
|
2,324 |
|
3,528 |
|||
Equity-method income (loss) |
|
(2) |
|
13 |
|||
Financial income |
|
92 |
|
127 |
|||
Financial expenses |
|
(584) |
|
(679) |
|||
Financial result |
|
(494) |
|
(539) |
|||
Income before income taxes |
|
1,830 |
|
2,989 |
|||
Income taxes |
|
(526) |
|
(222) |
|||
Income after income taxes |
|
1,304 |
|
2,767 |
|||
of which attributable to noncontrolling interest |
|
5 |
|
4 |
|||
of which attributable to Bayer AG stockholders (net income) |
|
1,299 |
|
2,763 |
|||
|
|
|
|
|
|||
€ |
|
|
|
|
|||
Earnings per share |
|
|
|
|
|||
Basic |
|
1.32 |
|
2.81 |
|||
Diluted |
|
1.32 |
|
2.81 |
|||
|
|||||||